Press releases

12 January, 2021

Abliva Announces Termination of License Agreement with Fortify Therapeutics

Abliva AB (Nasdaq Stockholm: ABLI) today announced that the license agreement with Fortify Therapeutics, a wholly-owned subsidiary of BridgeBio, regarding a development of a local treatment for Leber’ ...

17 November, 2020

Abliva receives positive regulatory feedback from UK MHRA on KL1333 Phase II/III study plan

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced it has received ...

10 November, 2020

Abliva initiates a drug-drug interaction study and paves the way for a KL1333 pivotal study in 2021

8 October, 2020

Regulatory

Magnus Persson leaves the Board of Directors of Abliva AB to focus on role as founding partner at Eir Ventures

Abliva AB (Nasdaq Stockholm: ABLI) today announces that Magnus Persson is leaving the company's Board of Directors at his own request, to focus on his role as founding Partner at Eir Ventures, a recen ...

7 October, 2020

Abliva doses the first patient in its KL1333 Phase Ia/b clinical study

Abliva AB (Nasdaq Stockholm: ABLI) today announced that the first primary mitochondrial disease patient in the company’s ongoing KL1333 Phase Ia/b study has been dosed. In this third part of the study ...

16 September, 2020

Abliva’s Mitochondria Day – today at 2 p.m. – 4 p.m. CEST

Abliva AB (Nasdaq Stockholm: ABLI) welcomes, on the occasion of The World Mitochondrial Disease Week, to its virtual Mitochondria Day 2020, today on 16 September at 2 p.m. – 4 p.m. CEST. The purpose o ...

9 September, 2020

Regulatory

Abliva intends to start a pivotal KL1333 study second half 2021

Abliva AB (Nasdaq Stockholm: ABLI) today announced that the company’s Board of Directors has decided to accelerate the KL1333 clinical program, with the intention to start a pivotal Phase II/III clini ...

26 August, 2020

Abliva arranges Mitochondria Day on 16 September 2020 – preliminary program

Abliva AB (Nasdaq Stockholm: ABLI) welcomes, on the occasion of The World Mitochondrial Disease Week, to its virtual Mitochondria Day 2020, on 16 September at 2 p.m. – 4 p.m. CEST. The purpose of the ...

12 August, 2020

Abliva arranges Mitochondria Day on 16 September 2020

10 July, 2020

Abliva receives positive FDA feedback on its KL1333 development plan

Abliva AB (Nasdaq Stockholm: ABLI) today announced that it has received positive feedback from the US Food and Drug Administration (“FDA”) on its KL1333 clinical development plan for the treatment of ...

23 June, 2020

Abliva – Virtual Capital Markets Day today at 3.00 p.m.

Abliva AB (Nasdaq Stockholm: ABLI) – today, 23 June 2020, holds a virtual Capital Markets Day. The theme of the day will be the company's new strategic focus on primary mitochondrial disease, the most ...

16 June, 2020

Abliva invites you to a virtual Capital Markets Day on June 23

Abliva AB (Nasdaq Stockholm: ABLI), invites you to a virtual Capital Markets Day on 23 June at 3.00 p.m. - 4.30 p.m. The theme of the day will be the company's new strategic focus on primary mitochond ...